When does the Prolia (denosumab) patent expire?
Prolia (denosumab) is covered by multiple patents and patent-protection periods, which can vary by country and by what type of claim is involved (composition of matter vs. method-of-use vs. manufacturing/other IP). The most reliable way to track the controlling expiries for Prolia is to check a live patent database that lists specific patent numbers and jurisdictions.
DrugPatentWatch.com compiles denosumab-related patent information, including when protections are expected to end for key patents tied to products like Prolia. See: DrugPatentWatch.com – Prolia (denosumab) patents and expiration info [1].
What patents cover denosumab for Prolia, and how do they differ from other denosumab products?
Denosumab is marketed in multiple indications under different brands (for example, Prolia for osteoporosis and Xgeva for oncology-related bone disease). Patent coverage can differ between brands even when the active ingredient is the same, because companies often file separate patent sets around:
- specific formulations or presentations,
- dosing regimens and therapeutic uses,
- manufacturing/process claims,
- and jurisdiction-specific enforcement strategy.
That means “denosumab patent expiry” is not always a single date. Patent-watch sites like DrugPatentWatch.com break down the underlying patents and help pinpoint which ones are relevant to Prolia specifically. [1]
Are there biosimilars for denosumab that could enter before Prolia’s patent expiry?
For biologics, market entry timing usually depends on a mix of:
- patent expiry and any patent challenges/litigation outcomes,
- regulatory exclusivity periods,
- and approval timing for any biosimilar candidate.
Because denosumab protections can be layered, a biosimilar’s earliest possible entry is tied to the earliest expiry among the patents that still block competitive marketing in a given jurisdiction. Patent data tools can help map those dates for Prolia. [1]
How do denosumab patent disputes affect market entry dates?
Even if a patent is scheduled to expire on paper, litigation or settlement terms can change the practical timeline for launch of competing products. The key practical question is whether any still-in-force patents are enforced against biosimilar entry attempts, and what courts or settlements require companies to do.
Patent trackers are useful here because they often list which patents are being asserted and track expiries. [1]
What should patients or prescribers know about “patent expiry” for Prolia?
Patent expiry is a drug-pricing and access issue as much as it is an IP issue. It does not automatically mean lower costs or guaranteed availability on the exact expiry date. What matters in practice is:
- whether biosimilars or competitors receive approval in the same jurisdiction, and
- whether remaining patents are still blocking marketing,
- plus reimbursement and formulary decisions.
For concrete expiry and patent listings, use a tracker with current patent schedules. [1]
Source
[1] https://www.drugpatentwatch.com/patent/Prolia-denosumab